Nalaganje...
A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans
Empagliflozin (formerly known as BI 10773) is a potent, competitive, and selective inhibitor of the sodium glucose transporter SGLT2, which mediates glucose reabsorption in the early proximal tubule and most of the glucose reabsorption by the kidney, overall. Accordingly, empagliflozin treatment inc...
Shranjeno v:
| izdano v: | Naunyn Schmiedebergs Arch Pharmacol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2015
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5896322/ https://ncbi.nlm.nih.gov/pubmed/26108304 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00210-015-1134-1 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|